BCL2 and Parkinson disease: Another active compound, Ginkgetin, investigated in experimental PD models triggered by MPP+, under both in vitro and in vivo conditions, lowers intracellular reactive oxygen species, protects mitochondrial membrane potential, blocks apoptosis via the caspase-3 and Bcl-2/Bax pathway, and modulates iron metabolism [9].